|
US5744500A
(en)
|
1990-01-03 |
1998-04-28 |
Teva Pharmaceutical Industries, Ltd. |
Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
|
|
IL118836A
(en)
|
1996-07-11 |
2001-01-11 |
Teva Pharma |
Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
|
|
AU775885B2
(en)
|
1999-10-27 |
2004-08-19 |
Teva Pharmaceutical Industries Ltd. |
Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder
|
|
EP1567152B1
(en)
|
2002-11-15 |
2013-08-14 |
Teva Pharmaceutical Industries Limited |
Use of rasagiline with riluzole to treat amyotrophic lateral sclerosis
|
|
GB2411355B
(en)
|
2004-02-27 |
2006-02-22 |
Niche Generics Ltd |
Pharmaceutical composition
|
|
EP1778196A4
(en)
*
|
2004-07-26 |
2008-12-17 |
Teva Pharma |
PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE
|
|
ATE365546T1
(de)
*
|
2004-11-10 |
2007-07-15 |
Teva Pharma |
Verfahren zur herstellung von komprimierten festen dosierungsformen, das gut zur verwendung mit schlecht wasserlöslichen arzneistoffen geeignet ist, und danach hergestellte komprimierte feste dosierungsformen
|
|
US8367105B2
(en)
|
2004-11-10 |
2013-02-05 |
Teva Pharmaceutical Industries, Ltd. |
Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
|
|
ATE521343T1
(de)
*
|
2004-11-24 |
2011-09-15 |
Teva Pharma |
Im mund zerfallende zusammensetzungen von rasagilin
|
|
US20100167983A1
(en)
*
|
2007-10-22 |
2010-07-01 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
|
|
ES2420404T3
(es)
*
|
2005-02-17 |
2013-08-23 |
Teva Pharmaceutical Industries Ltd. |
Terapia de combinación con acetato de glatiramero y rasagilina para el tratamiento de esclerosis múltiple
|
|
US7815942B2
(en)
*
|
2005-02-23 |
2010-10-19 |
Teva Pharmaceutical Industries, Ltd. |
Rasagiline formulations of improved content uniformity
|
|
US7491847B2
(en)
|
2005-11-17 |
2009-02-17 |
Teva Pharmaceutical Industries, Ltd. |
Methods for isolating propargylated aminoindans
|
|
US7572834B1
(en)
|
2005-12-06 |
2009-08-11 |
Teva Pharmaceutical Industries, Ltd. |
Rasagiline formulations and processes for their preparation
|
|
JP2009518433A
(ja)
|
2005-12-09 |
2009-05-07 |
イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム |
神経保護用の低用量ラドスチギルの使用
|
|
AU2007217349B9
(en)
|
2006-02-21 |
2013-06-27 |
Teva Pharmaceutical Industries, Ltd. |
Use of rasagiline for the treatment of Multiple System Atrophy
|
|
TW200744576A
(en)
|
2006-02-24 |
2007-12-16 |
Teva Pharma |
Propargylated aminoindans, processes for preparation, and uses thereof
|
|
CA2646250A1
(en)
|
2006-04-03 |
2007-10-18 |
Teva Pharmaceutical Industries Ltd. |
Use of rasagiline for the treatment of restless legs syndrome
|
|
DE202006020710U1
(de)
|
2006-05-09 |
2009-12-31 |
Teva Pharmaceutical Industries Ltd. |
Zusammensetzungen mit Rosiglitazonmaleat
|
|
EP1892233A1
(de)
*
|
2006-08-18 |
2008-02-27 |
Ratiopharm GmbH |
Neue Salze des Wirkstoffs Rasagilin
|
|
PT2101569E
(pt)
*
|
2006-12-14 |
2012-01-13 |
Teva Pharma |
Base de rasagilina sólida cristalina
|
|
EA016843B1
(ru)
|
2006-12-14 |
2012-07-30 |
Тева Фармасьютикал Индастриз, Лтд. |
Таннат разагилина
|
|
EP1987816A1
(de)
*
|
2007-04-30 |
2008-11-05 |
Ratiopharm GmbH |
Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
|
|
US20090062400A1
(en)
*
|
2007-09-05 |
2009-03-05 |
Laurence Oron |
Method of treating glaucoma using rasagiline
|
|
US8188149B2
(en)
*
|
2007-09-17 |
2012-05-29 |
Teva Pharmaceutical Industries, Ltd. |
Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
|
|
KR20100107028A
(ko)
*
|
2008-01-11 |
2010-10-04 |
테바 파마슈티컬 인더스트리즈 리미티드 |
라사길린 제형, 그들의 제법 및 용도
|
|
US20090247537A1
(en)
*
|
2008-03-25 |
2009-10-01 |
William Dale Overfield |
Methods for preventing or treating bruxism using dopaminergic agents
|
|
EP2271612B1
(en)
*
|
2008-03-31 |
2016-08-10 |
Actavis Group PTC EHF |
Rasagiline mesylate particles and process for the preparation thereof
|
|
BRPI0909894A2
(pt)
*
|
2008-06-13 |
2015-07-28 |
Teva Pharma |
"método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica.
|
|
US7968749B2
(en)
*
|
2008-06-19 |
2011-06-28 |
Teva Pharmaceutical Industries, Ltd. |
Process for preparing and drying solid rasagiline base
|
|
AU2009260733B2
(en)
*
|
2008-06-19 |
2015-01-29 |
Teva Pharmaceutical Industries, Ltd. |
Process for purifying rasagiline base
|
|
US20100189791A1
(en)
*
|
2009-01-23 |
2010-07-29 |
Teva Pharmaceutical Industries, Ltd. |
Delayed release rasagiline malate formulation
|
|
EP2218444A3
(en)
|
2009-01-23 |
2010-08-25 |
Teva Pharmaceutical Industries, Ltd. |
Delayed release rasagiline formulation
|
|
CN102341104A
(zh)
|
2009-03-05 |
2012-02-01 |
桑多斯股份公司 |
含有甲磺酸雷沙吉兰的药物组合物
|
|
PL2451771T3
(pl)
|
2009-07-09 |
2014-12-31 |
Ratiopharm Gmbh |
Sole rasagiliny i ich preparaty farmaceutyczne
|
|
CN102048717B
(zh)
*
|
2009-10-29 |
2014-02-19 |
重庆医药工业研究院有限责任公司 |
一种稳定的雷沙吉兰组合物
|
|
MX2012007375A
(es)
|
2009-12-22 |
2012-07-30 |
Teva Pharma |
3-ceto-n-propargil 1-aminoindano.
|
|
CN108186611A
(zh)
|
2010-04-30 |
2018-06-22 |
帝国制药美国公司 |
丙炔基氨基茚满透皮组合物
|
|
EP2389927A1
(en)
|
2010-05-30 |
2011-11-30 |
Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi |
Pharmaceutical formulations of rasagiline
|
|
EP2603212A4
(en)
|
2010-07-27 |
2014-01-08 |
Teva Pharma |
USE OF RASAGILINE FOR THE TREATMENT OF SMOKING DISORDER
|
|
JP2013537530A
(ja)
|
2010-07-27 |
2013-10-03 |
テバ ファーマシューティカル インダストリーズ リミティド |
ラサギリンシトレートの分散物
|
|
KR101853082B1
(ko)
|
2011-03-24 |
2018-04-27 |
테이코쿠 팔마 유에스에이, 인코포레이티드 |
활성제층 및 활성제 변환층을 포함하는 경피 조성물
|
|
BR112014008555A2
(pt)
*
|
2011-10-10 |
2017-04-18 |
Teva Pharma |
r(+)-n-formil-propargil-aminoindano
|
|
AU2012323351A1
(en)
|
2011-10-10 |
2014-05-22 |
Teva Pharmaceutical Industries Ltd. |
R(+)-N-methyl-propargyl-aminoindan
|
|
US20130089611A1
(en)
*
|
2011-10-10 |
2013-04-11 |
Teva Pharmaceutical Industries, Ltd. |
Rasagiline citramide
|
|
EP2776020B1
(en)
|
2011-11-09 |
2019-09-11 |
Teikoku Seiyaku Co., Ltd. |
Methods for the treatment of skin neoplasms
|
|
DE102012000786A1
(de)
|
2012-01-18 |
2013-07-18 |
Stada Arzneimittel Ag |
Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung, enthaltend den Wirkstoff Rasagilin
|
|
ES2584059T3
(es)
|
2012-03-21 |
2016-09-23 |
Synthon Bv |
Composiciones farmacéuticas estabilizadas que comprenden sales de rasagilina
|
|
WO2013175493A1
(en)
|
2012-04-09 |
2013-11-28 |
Cadila Healthcare Limited |
Stable oral pharmaceutical compositions
|
|
WO2014028868A1
(en)
|
2012-08-17 |
2014-02-20 |
Teva Pharmaceutical Industries Ltd. |
Parenteral formulation of rasagiline
|
|
AU2013338243B2
(en)
|
2012-11-02 |
2016-09-29 |
Teikoku Seiyaku Co., Ltd. |
Propynylaminoindan transdermal compositions
|
|
EP2764862A1
(en)
*
|
2013-02-06 |
2014-08-13 |
Galenicum Health S.L. |
Immediate release tablets of rasagiline hemitartrate
|
|
ES2524865T1
(es)
*
|
2013-02-06 |
2014-12-15 |
Galenicum Health S.L. |
Composiciones farmacéuticas estables en forma de comprimidos de liberación inmediata
|
|
CN115400090A
(zh)
*
|
2022-10-09 |
2022-11-29 |
北京新领先医药科技发展有限公司 |
一种雷沙吉兰的口崩片组合物及其制备方法
|